Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2023-03-22 Annual Report
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Annual Report to shareholders 67 pages 941.6KB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022' and contains detailed sections typical of an annual report, including a Chairman and CEO review, Directors' report, financial statements (profit or loss, financial position, cash flows), notes to financial statements, Directors' declaration, and Independent Auditor's Report. The content includes comprehensive financial data, operational highlights, corporate governance information, and auditor's independence declaration. The document length is 15,000 characters, indicating a full report rather than a brief announcement. There is no indication that this is merely an announcement of the report's publication or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-03-22 English
Appendix 4G and Corporate Governance Statement 19 pages 529.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a completed Appendix 4G form, which is a key to corporate governance disclosures and a verification tool for compliance with ASX Listing Rule 4.10.3. The document includes detailed checklists of governance principles and recommendations, indicating which have been followed or not, and references the corporate governance statement located on the company's website. It is not the corporate governance statement itself, nor is it an annual report or a full governance report. Appendix 4G is a specific regulatory filing required to be lodged with ASX alongside the annual report but is a separate document. Given the nature and content, this document fits the category of Regulatory Filings (RNS) as it is a compliance document related to governance disclosures but not the full governance report or annual report itself.
2023-03-22 English
Gold Coast Hospital to begin trial of the HeraCARE Platform 3 pages 151.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 21 March 2023 from HeraMED Limited regarding a Memorandum of Understanding (MoU) with the Gold Coast Hospital and Health Service to trial the HeraCARE platform for maternity care. It describes the trial, strategic partnership, and an upcoming investor webinar. There are no financial statements, quarterly or annual results, or detailed financial data. The content is primarily an announcement of a business development and partnership, not a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a call transcript or governance information. The document is a corporate announcement about a new trial and partnership, which aligns best with a general Regulatory Filing (RNS) as it is a regulatory announcement to the market about a material business development. The document length is 6792 characters, which is consistent with a detailed announcement but not a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-03-20 English
Proposed issue of securities - HMD 6 pages 30.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Heramed Limited. It details the terms of a non pro rata offer of securities under a disclosure document or product disclosure statement (PDS), including the number of securities, offer price, and timetable. The document is structured as an official announcement to the ASX (Australian Securities Exchange) about the proposed securities issuance, including compliance with listing rules and placement capacity. It does not contain financial statements or detailed financial performance data, nor is it a transcript, report, or presentation. It is clearly an update on capital raising activity and changes to the company's capital structure. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (8610 characters) and content confirm it is a full announcement rather than a brief notice or a report publication announcement.
2023-02-28 English
Cleansing Prospectus 30 pages 301.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'PROSPECTUS' and details an offer of listed options in the company's capital. It includes sections such as corporate directory, timetable, details of the offer, purpose and effect of the offer, rights and liabilities attaching to securities, risk factors, and additional information. The document is prepared under section 708A(11) of the Corporations Act to remove trading restrictions on the sale of listed options. It is clearly an offering document aimed at investors to raise capital or facilitate trading of securities. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not an annual report, earnings release, or any other report type but a prospectus for a securities offering.
2023-02-28 English
Appendix 2A 21 pages 382.6KB
Regulatory Filings Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the securities to be quoted, issue dates, and other regulatory compliance details related to securities quotation. This type of document is a regulatory announcement related to capital markets activity, specifically the listing or quotation of securities. It is not a financial report, earnings release, management discussion, or any other type of report. It is a formal regulatory filing notifying the exchange and the market about the application for quotation of securities. Therefore, the most appropriate classification is 'Regulatory Filings' (RNS), as it is a general regulatory announcement that does not fit into more specific categories like capital/financing update or share issue/capital change, since it is an application for quotation rather than the issuance itself or a financing update.
2023-02-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.